{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:32:43Z","timestamp":1790271163207,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13104-017-2500-5","type":"journal-article","created":{"date-parts":[[2017,5,8]],"date-time":"2017-05-08T10:05:58Z","timestamp":1494237958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Ivermectin induced Steven\u2013Johnsons syndrome: case report"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7557-7777","authenticated-orcid":false,"given":"Desmond","family":"Aroke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego Nitcheu","family":"Tchouakam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis Tazinya","family":"Awungia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvester Yari","family":"Mapoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart Ndutard","family":"Ngassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin Momo","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,8]]},"reference":[{"issue":"7","key":"2500_CR1","first-page":"625","volume":"13","author":"M Paulmann","year":"2015","unstructured":"Paulmann M, Mockenhaupt M. Severe drug-induced skin reactions: clinical features, diagnosis, etiology, and therapy. J Dtsch Dermatol Ges. 2015;13(7):625\u201345.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"2500_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S2222-1808(13)60051-1","volume":"3","author":"P Tiwari","year":"2013","unstructured":"Tiwari P, Panik R, Bhattacharya A, Ahirwar D, Chandy A. Toxic epidermal necrolysis : an update. Asian Pac J Trop Dis. 2013;3(2):85\u201392.","journal-title":"Asian Pac J Trop Dis"},{"issue":"2","key":"2500_CR3","first-page":"618","volume":"2","author":"S Tyagi","year":"2010","unstructured":"Tyagi S, Kumar S, Kumar A, Singla M, Singh A. Stevens\u2013Johnson syndrome\u2014a life threatening skin disorder: a review. J Chem Pharm Res. 2010;2(2):618\u201326.","journal-title":"J Chem Pharm Res"},{"issue":"2","key":"2500_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.4103\/0022-3859.81865","volume":"57","author":"M Barvaliya","year":"2011","unstructured":"Barvaliya M, Sanmukhani J, Patel T, Paliwal N, Shah H, Tripathi C. Drug-induced Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: a multicentric retrospective study. J Postgr Med. 2011;57(2):115\u20139.","journal-title":"J Postgr Med"},{"issue":"4","key":"2500_CR5","first-page":"96","volume":"10","author":"SA Bhounsule","year":"2015","unstructured":"Bhounsule SA, Bandodkar LV, Samuel LJ. Retrospective analysis of deaths due to drug- induced Stevens\u2013Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in inpatients admitted in the dermatology unit of a tertiary care hospital. J Pharm Biol Sci. 2015;10(4):96\u20139.","journal-title":"J Pharm Biol Sci"},{"key":"2500_CR6","doi-asserted-by":"publisher","first-page":"9071","DOI":"10.1186\/1757-1626-2-9071","volume":"2","author":"UR Ofoma","year":"2009","unstructured":"Ofoma UR, Chapnick EK. Fluconazole induced toxic epidermal necrolysis: a case report. Cases J. 2009;2:9071. doi:\n                        10.1186\/1757-1626-2-9071\n                        \n                    .","journal-title":"Cases J"},{"key":"2500_CR7","doi-asserted-by":"publisher","first-page":"481","DOI":"10.4236\/ijcm.2011.24082","volume":"2","author":"E Adinma","year":"2011","unstructured":"Adinma E, Ezeama NN, Umeokonkwo CD. Streptomycin-induced Steven\u2013Johnson syndrome in a HIV sero-positive patient with tuberculosis: a case report. Int J Clin Med. 2011;2:481\u20133.","journal-title":"Int J Clin Med"},{"issue":"Suppl 1","key":"2500_CR8","doi-asserted-by":"publisher","first-page":"S278","DOI":"10.4103\/0976-237X.166838","volume":"6","author":"R Rajput","year":"2015","unstructured":"Rajput R, Sagari S, Durgavanshi AKA. Paracetamol induced Steven\u2013Johnson syndrome. A rare case report. Contemp Clin Dent. 2015;6(Suppl 1):S278\u201381.","journal-title":"Contemp Clin Dent"},{"key":"2500_CR9","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1056\/NEJM199306103282304","volume":"328","author":"SA Coopman","year":"1993","unstructured":"Coopman SA, Johnson RA. PR and SRS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med. 1993;328:1670\u20134.","journal-title":"N Engl J Med"},{"key":"2500_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1472-6904-7-8","volume":"7","author":"KJ Patel","year":"2007","unstructured":"Patel KJ, Kedia MS, Bajpai D, Mehta SS, Kshirsagar NAGN. Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study. BMC Clin Pharmacol. 2007;7:8.","journal-title":"BMC Clin Pharmacol"},{"key":"2500_CR11","first-page":"95","volume":"47","author":"VK Sharma","year":"2001","unstructured":"Sharma VK, Sethuraman GKB. Cutaneous adverse drug reactions: clinical pattern and causative agents\u2014a 6\u00a0year series from Chandigarh, India. J Postgr Med. 2001;47:95\u20139.","journal-title":"J Postgr Med"},{"key":"2500_CR12","first-page":"15","volume":"42","author":"VK Sharma","year":"1996","unstructured":"Sharma VK, Sethuraman G. Adverse cutaneous reactions to drugs: an overview. J Postgr Med. 1996;42:15\u201322.","journal-title":"J Postgr Med"},{"issue":"4","key":"2500_CR13","doi-asserted-by":"publisher","first-page":"430","DOI":"10.4103\/0378-6323.42883","volume":"74","author":"RM Patel","year":"2008","unstructured":"Patel RM, Marfatia YS. Clinical study of cutaneous drug eruptions in 200 patients. Indian J Dermatol Venereol Leprol. 2008;74(4):430.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"3","key":"2500_CR14","first-page":"124","volume":"20","author":"R Lehloenya","year":"2007","unstructured":"Lehloenya R. Management of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis. Curr Allergy Clin Immunol. 2007;20(3):124\u20138.","journal-title":"Curr Allergy Clin Immunol"},{"issue":"3","key":"2500_CR15","first-page":"325","volume":"15","author":"LH Kircik","year":"2016","unstructured":"Kircik LH, Del Rosso JQ, Layton AMSJ. Over 25\u00a0years of clinical experience with ivermectin: an overview of safety for an increasing number of indications. J Drugs Dermatol. 2016;15(3):325\u201332.","journal-title":"J Drugs Dermatol"},{"key":"2500_CR16","unstructured":"Nirken MH. Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in adults. \n                        http:\/\/uptodateonline.com\/patients\/content\/topic.do?topicKey=~KMM0KgcQUwSCr8z\n                        \n                    . Accessed 5 Jan 2017"},{"key":"2500_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000083947","volume":"136","author":"P Paquet","year":"2005","unstructured":"Paquet P, Pierard GEQP. Novel treatments for drug-induced toxic epidermal necrolysis (Lyell\u2019s syndrome). Int Arch Allergy Immunol. 2005;136:205\u201316.","journal-title":"Int Arch Allergy Immunol"},{"key":"2500_CR18","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/0190-9622(90)70333-D","volume":"23","author":"JC Roujeau","year":"1990","unstructured":"Roujeau JC, Chosidow O, Saiag PGJ. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol. 1990;23:1039\u201358.","journal-title":"J Am Acad Dermatol"},{"key":"2500_CR19","unstructured":"Praag EV. Ivermectin. In: Drugs for rabbits. 2009. p. 2\u20135. \n                        http:\/\/www.medirabbit.com\/Safe_medication\/Anti_parasitics\/ivermectin.PDF"},{"key":"2500_CR20","unstructured":"Richard F, Michelle A. Clark LXC. Lippincott\u2019s illustrated reviews: pharmacology, 4th ed. In: Richard A, Harvey PCC, editors. Philadelphia: Lippincott Williams & Wilkins; 2009."},{"issue":"1","key":"2500_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1590\/S0103-64402004000100015","volume":"15","author":"EH Shinohara","year":"2004","unstructured":"Shinohara EH, Martini MZ, Gomes H, Neto DO. Oral myiasis treated with ivermectin: case report. Braz Dent J. 2004;15(1):79\u201381.","journal-title":"Braz Dent J"},{"issue":"1","key":"2500_CR22","first-page":"1","volume":"160","author":"D Catherine","year":"2014","unstructured":"Catherine D, Susana F, Elisabeth G, Martine M, Christian S. Encephalopathy due to prolonged misuse of ivermectin (Stromectol\u00ae) after scabies infection. Clin Toxicol. 2014;160(1):1.","journal-title":"Clin Toxicol"},{"issue":"1","key":"2500_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1086\/509325","volume":"44","author":"DN Udall","year":"2007","unstructured":"Udall DN. Recent updates on onchocerciasis: diagnosis and treatment. CID. 2007;44(1):53\u201360.","journal-title":"CID"},{"issue":"49","key":"2500_CR24","first-page":"545","volume":"374","author":"WHO","year":"2014","unstructured":"WHO. African programme for onchocerciasis control: progress report, 2013\u20132014. Wkly Epidemiol Rec. 2014;374(49):545\u201360.","journal-title":"Wkly Epidemiol Rec"},{"key":"2500_CR25","unstructured":"WHO. Prevention, control and elimination of onchocerciasis; 2015. \n                        http:\/\/www.who.int\/onchocerciasis\/control\/en\/\n                        \n                    . Accessed 5 Jan 2017"},{"key":"2500_CR26","unstructured":"MSD BV. Stromectol (Ivermectin) tablets; 2009. p. 1\u20136. \n                        http:\/\/www.medsafe.govt.nz\/profs\/Datasheet\/s\/Stromectoltab.pdf\n                        \n                    . Accessed 5 Jan 2017"},{"key":"2500_CR27","unstructured":"U.S. Food and Drug Administration Medwatch. What is a serious adverse event? \n                        http:\/\/www.fda.gov\/medwatch\/report\/DESK\/advevnt.htm\n                        \n                    . Accessed 5 Jan 2017"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-017-2500-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,8]],"date-time":"2017-05-08T10:06:12Z","timestamp":1494237972000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-017-2500-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,8]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2500"],"URL":"https:\/\/doi.org\/10.1186\/s13104-017-2500-5","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,8]]},"article-number":"179"}}